Grifols (G0F) Stock Overview
Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
G0F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.46 |
| 52 Week High | €6.60 |
| 52 Week Low | €4.04 |
| Beta | 1.17 |
| 1 Month Change | 1.83% |
| 3 Month Change | -15.85% |
| 1 Year Change | 2.29% |
| 3 Year Change | -16.64% |
| 5 Year Change | n/a |
| Change since IPO | -41.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| G0F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.7% | -1.0% | 0.6% |
| 1Y | 2.3% | -11.9% | 0.2% |
Return vs Industry: G0F exceeded the German Biotechs industry which returned -11.3% over the past year.
Return vs Market: G0F exceeded the German Market which returned -0.1% over the past year.
Price Volatility
| G0F volatility | |
|---|---|
| G0F Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: G0F's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G0F's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 25,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
Grifols, S.A. Fundamentals Summary
| G0F fundamental statistics | |
|---|---|
| Market cap | €5.84b |
| Earnings (TTM) | €415.00m |
| Revenue (TTM) | €7.44b |
Is G0F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G0F income statement (TTM) | |
|---|---|
| Revenue | €7.44b |
| Cost of Revenue | €4.58b |
| Gross Profit | €2.85b |
| Other Expenses | €2.44b |
| Earnings | €415.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 38.36% |
| Net Profit Margin | 5.58% |
| Debt/Equity Ratio | 109.9% |
How did G0F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 16:04 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |